A New Standard for Extended Endocrine Therapy Decision-Making
Extending endocrine therapy beyond 5 years has been shown to reduce the risk of recurrence in some women with HR+, early-stage breast cancer. However, longer treatment is associated with significant potential side effects and adverse events, and many women do not benefit.
Breast Cancer Index is a unique, proprietary genomic test that helps inform the appropriate duration of endocrine therapy by reporting two pieces of critical information:
- Is she likely to benefit from extended endocrine therapy?
- What is her individual risk of late distant recurrence (5-10 years post-diagnosis)?
SABCS 2023
Watch Drs. Rena Callahan*, UCLA Health, and VK Gadi*, University of Illinois Cancer Center, discuss evolving trends in HR+, early-stage breast cancer diagnostics.
JADPRO Live 2023
Watch a panel discussion on strategies to avoid over- and under-treatment in HR+, early-stage breast cancer with Linda Moors*, PA-C, Marla Sustin*, NP, and Mayra Lima*, APRN, MSN.
Hologic’s Breast Continuum of Care
From screening to survivorship, Hologic’s innovative and trusted breast health solutions help healthcare providers support women through their entire breast health journey. We apply cutting-edge science to accelerate discovery, improve efficiency and continually sharpen precision.
For Breast Cancer Index Intended Use and Limitations, visit the full site.
Biotheranostics, Inc., A Hologic Company
6333 Sequence Dr.,
San Diego, CA 92121
1 (877) 886-6739
